Article
Dr. Jack Cush reviews the FDA approvals, news and the latest journal articles from the past week on RheumNow.com.
All News
Article
Dr. Jack Cush reviews this week’s news and journal reports featured on RheumNow.com.
Article
RheumNow Live (RNL) for 2021 was held March 20 - 21 in Fort Worth, TX, and now all can partake in the meeting - by video, podcast or by signing up for Tuesday Nite Rheumatology (TNR).
Richard Conway
Tweet
@DrDDRheum presents on uveitis in SpA. AxSpA>PsA, 30% vs 7.6%. PsA: B27+⬆️ risk, smoking ⁉️ and DMARDs protective. AxSpA: Elevated CRP⬆️ risk, biologics protective. Abstr#0064 #ACR21 @RheumNow https://t.co/psw20RGDst
Dr. John Cush
Tweet
ICYMI: Risk of anterior uveitis w/ secukinumab is equal to etanercept; but both inferior to mAb TNFi (infliximab, adalimumab) ~ 5000 Rx starts, AU risk/100PY = SEC 6.8; ETA 7.5; INFLIX 2.9; ADA 4. SEC has a 2.3 fold greater risk than ADA/INFX https://t.co/DB9G2mz4mN https://t.co/91FbwCYsmj
Dr. John Cush
Tweet
Prescribe antimalarial dosages at 5 mg/kg/d or less.... A baseline retinal exam w/ optical coherence tomography should be performed w/in 6 mos...to rule out confounding Dz. Pts at low risk for retinopathy do not require annual screening until 5 years.. https://t.co/l3sCxOJLNJ
Dr. John Cush
Tweet
500 Turkish pts from 4 pediatric rheum clinics. Oligoart. JIA (oJIA) was most common (39%), then enthesitisJIA (ERA-23%), RF neg polyarthritis (16%), RF+ poly (2.2%), Systemic JIA (16%), juvenile PsA (5.2%). Uveitis most common in oJIA (13%), then ERA (5%) https://t.co/a7O1RBM1xJ https://t.co/woSafvVsmA
Dr. John Cush
Tweet
ICYMI: One of our top June videos
WATCH: Is blindness with Tocilizumab in GCA a worry?
Dr. David Liew ( @drdavidliew ) weighs in. #EULAR2021
https://t.co/eFrmbkW9Gy https://t.co/4tY3hEDj2j
Vanessa Ocampo - MD
Tweet
Top 10 things you should know about THE EYE in your rheumatology practice @CRASCRRheum
#uveitisclinic
#uveitisrheumatologyclinic
#kensingtoneyeinstitute https://t.co/SqRKOYa2N0
Dr. John Cush
Tweet
Study of 33 RCTs, 4544 pts Rx w/ either IL-17 or TNF inhibitors finds lower risk of UVEITIS with anti-TNF mAb (vs PBO OR = 0.46; vs IL-17i OR = 0.34. IL-17 inhibitors are not protective against uveitis https://t.co/AIxgI2qhq9
Dr. John Cush
Tweet
WATCH: Is blindness with Tocilizumab in GCA a worry?
Dr. David Liew ( @drdavidliew) weighs in. #EULAR2021
https://t.co/eFrmbkW9Gy https://t.co/imMaEIczb8
Dr. John Cush
Tweet
The Swedish Rheumatology Quality Register looked at risk of ant.uveitis (AU). From 4851 starting secukinumab (456) or TNFinhibitor (4395 ), there was higher AU risk w/ SEC (adj HR 2.32; 1.16-4.63) & ETN (1.82;1.13-2.93) (ADA as referent) https://t.co/j06MtKedYU
Dr. John Cush
Tweet
Video: Prevalence of Long Term HCQ in Retinal Toxicity: Dr. Kathryn Dao (@KDAO2011 )
Dr. Kathryn Dao reviews abstract OP0133, "The Prevalence and Risk Factors of Retinal Toxicity Associated with Long-Term Hydroxychloroquine Use", presented at #EULAR2021.
https://t.co/tZyXQhZgLG https://t.co/x6AfItFWEU
Meral K. El Ramahi, MD
Tweet
#EULAR2021 - Key points from Dr. Mease's oral abstract:
⭐️AxSpA pts were younger & more likely to be male & have a hx of uveitis & IBD
⭐️AxSpA pts had less exposure to prior therapies relative to axPsA pts
⭐️AxSpA assoc w/ > spinal pain regardless of b/tsDMARD status
@Rheumnow
Meral K. El Ramahi, MD
Tweet
#EULAR2021: SpA pts w/ predominant axial phenotype tended to be HLAB27+ & have uveitis whereas those w/ predom peripheral phenotype tended to have arthritis, dactylitis, or psoriasis & fit a clinical dx of axSpA & psSpa (incl psA) respectively per this observat study. @RheumNow https://t.co/E5UTbc6Sqb
Richard Conway
Tweet
Dr Sanchez-Bilbao presents surprising data that tocilizumab may improve even permanent vision loss in GCA @RheumNow #EULAR2021 Abstr#OP0065 https://t.co/oFGNZ04oKr
Dr. John Cush
Tweet
#LupusAwarenessMonth
Dr. Kathryn Dao - Risk of Hydroxychloroquine Retinal Toxicity
From ACR 2020
https://t.co/7BCVvMOm0T https://t.co/PhHubO7rxG
Dr. John Cush
Tweet
#RNL2021 coverage from Dr. Rachel Tate @uptoTate
Dr. Robert Wang: 91% of uveitis is non-infectious and located in the front of the eye - "anterior uveitis/iritis." 50% of anterior uveitis patients are +HLA B27! #RheumNow
Dr. John Cush
Tweet
#RNL2021 coverage from @uptoTate
"Dr. Robert Wang: 91% of uveitis is non-infectious and located in the front of the eye - "anterior uveitis/iritis." 50% of anterior uveitis patients are +HLA B27! "
#RheumNowLive
Dr. John Cush
Tweet
Great coverage of #RNL2021 from Dr. Robert Chao @doctorRBC
Fascinating talk by Dr. Robert Wang on uveitis. Pearls:
-Anterior uveitis with hypopyon, will be B27+
-Hypopyon can be 2/2 Behcets and endopthalmitis
-work up for Uveitis: B27, ACE/CXR, syphilis test
#RNL2021 https://t.co/9DdNaAt7lx
